Literature DB >> 29862655

Comparison of corneal collagen cross-linking (PACK-CXL) and voriconazole treatments in experimental fungal keratitis.

Hüseyin Baran Özdemir1, Ayşe Kalkancı2, Kamil Bilgihan3, Pınar Uyar Göçün4, Betül Öğüt4, Funda Karakurt2, Merve Erdoğan2.   

Abstract

PURPOSE: To compare the antifungal efficacy of corneal collagen cross-linking with photoactivated riboflavin (PACK-CXL) and voriconazole in experimental Fusarium solani and Candida albicans keratitis models.
METHODS: Sixty-four corneas of 32 New Zealand rabbits were included and divided into two main groups. Intrastromal injection of Fusarium and Candida suspensions was performed, and it was observed that keratitis was formed on the third day. Both groups were randomly separated into the following four groups: control, PACK-CXL, voriconazole and PACK-CXL combined with voriconazole. PACK-CXL was applied using 0.25% riboflavin in an accelerated Dresden protocol (total ultraviolet A dose 5.4 J/cm²). Voriconazole was applied topically as 7x1/day with a dose of 1% (10 mg/ml). Corneal buttons were excised on the tenth day, and microbiological and pathological examinations were performed.
RESULTS: The PACK-CXL and PACK-CXL combined with voriconazole groups each had 100 colony-forming unit (CFU/ml) of reproduced micro-organisms compared with 500 CFU/ml in the voriconazole group and 1500 CFU/ml in the control group (p < 0.001) in the Fusarium keratitis model. The PACK-CXL combined with voriconazole group had 100 CFU/ml, the PACK-CXL group had 150 CFU/ml, and the voriconazole group had 200 CFU/ml of reproduced micro-organisms compared with 4000 CFU/ml in the control group (p < 0.002) in the Candida keratitis model. (p < 0.001). Fewer hyphae and non-specific stromal changes were observed in the pathological cross sections examined in subgroups that used CXL.
CONCLUSION: There was less fungus reproduction and a lower keratitis score for Fusarium solani and Candida albicans in the treatment groups compared to the control groups, especially in groups that used PACK-CXL. These results suggest that it is useful to combine PACK-CXL treatment with medical treatment in the fungal keratitis algorithm at the early stage of the disease.
© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  PACK-CXL; corneal cross-linking; fungal keratitis; voriconazole

Mesh:

Substances:

Year:  2018        PMID: 29862655     DOI: 10.1111/aos.13829

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  6 in total

1.  Comparison of modified corneal cross-linking with intrastromal voriconazole for the treatment of fungal corneal ulcer.

Authors:  Yingxin Chen; Xingya Miao; Minghong Gao; Lixin Song
Journal:  Exp Ther Med       Date:  2021-05-21       Impact factor: 2.447

2.  Comparison of Accelerated and Standard Corneal Collagen Cross-Linking Treatments in Experimental Fungal Keratitis for Aspergillus fumigatus.

Authors:  Anji Wei; Zhennan Zhao; Xiangmei Kong; Tingting Shao
Journal:  J Ophthalmol       Date:  2022-07-20       Impact factor: 1.974

3.  Comparison of Corneal Collagen Cross-Linking and Voriconazole Treatments in Experimental Fungal Keratitis for Aspergillus fumigatus.

Authors:  Zhennan Zhao; Xueli Chen; Yi Shao; Tingting Shao
Journal:  Front Med (Lausanne)       Date:  2022-06-28

4.  Commentary: PACK-CXL in fungal keratitis.

Authors:  Rashmi Deshmukh
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

5.  Corneal Cross-Linking Window Absorption (CXL-WA) as an Adjuvant Therapy in the Management of Aspergillus niger Keratitis.

Authors:  Pietro Rosetta; Emanuela F Legrottaglie; Luca Pagano; Paolo Vinciguerra
Journal:  Case Rep Ophthalmol Med       Date:  2018-12-10

6.  Rabbit Fungal Keratitis Model of Fusarium solani Tested Against Three Commercially Available Antifungal Drugs.

Authors:  Thet Tun Aung; Wei Hong Jeff Chor; Myoe Naing Lynn; Anita Sook Yee Chan; Donald T H Tan; Roger W Beuerman
Journal:  Eye Contact Lens       Date:  2020-09       Impact factor: 3.152

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.